- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or refractory multiple myeloma (RRMM)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Elranatamab – March 2025
Elranatamab; Solution for subcutaneous injection 44 mg in 1.1 mL (40 mg per mL), Solution for subcutaneous injection 76 mg in 1.9 mL (40 mg per mL); Elrexfio®
Last updated
12 March 2025